Reference Detail

Ref Type

PMID

Authors

V.T. Phan, E. Verner, M. Gerritsen, J.M. Bradshaw, D.M. Goldstein, R.J. Hill, D. Karr, J. LaStant, P. Nunn, D. Tam, J. Shu, J.O. Funk, K. Brameld

Title

Irreversible Covalent Pan-FGFR Inhibitors are Highly Efficacious Against FGFR-dependent Cancers

Journal	Vol	Issue	Date	Pages	Journal Short Title
European Journal of Cancer

URL

Abstract Text

Eu J Cancer Nov 2014 Volume 50, Supplement 6, Page 157

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
PRN1109	PRN1109	1	0
PRN1371	PRN1371	18	1

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
PRN1109		PRN 1109\|PRN-1109	FGFR Inhibitor (Pan) 26	PRN1109 is a pan-FGFR inhibitor that blocks FGF/FGFR signaling, leading to anti-tumor activities (Eu J Cancer 2014 Vol 50, Suppl 6:157).
PRN1371			FGFR Inhibitor (Pan) 26	PRN1371 is an irreversible inhibitor of FGFR1-4 that blocks FGFR signaling, leading to apoptosis and tumor regression in animal models (Eu J Cancer 2014 Vol 50, Suppl 6:157, PMID: 31167419).

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FGFR2 amp	stomach cancer	predicted - sensitive	PRN1109	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRN1109 treatment resulted in tumor regression in gastric cancer cell line xenograft models harboring FGFR2 amplification (Eu J Cancer 2014 Vol 50, Suppl 6:157).	detail...